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Abstract
Background: Although the recreational use of psychoactive substances is common there is only limited systematic
collection of data on acute drug toxicity or hospital presentations, in particular regarding novel psychoactive
substances (NPS) that have emerged on the illicit market in the last years.
Methods: We included all cases presenting at the emergency department (ED) of the University Hospital of Basel,
Switzerland, between October 2014 and September 2015 with acute toxicity due to self-reported recreational drug
use or with symptoms/signs consistent with acute toxicity. Intoxications were confirmed using immunoassays and
LC-MS/MS, detecting also novel psychoactive substances.
Results: Among the 50’624 attendances at the ED, 210 were directly related to acute toxicity of recreational drugs. The
mean patient age was 33 years and 73 % were male. Analytical drug confirmation was available in 136 cases. Most
presentations were reportedly related to cocaine (33 %), cannabis (32 %), and heroin (14 %). The most commonly
analytically detected substances were cannabis (33 %), cocaine (27 %), and opioids excluding methadone (19 %). There
were only two NPS cases; a severe intoxication with paramethoxymethamphetamine (PMMA) in combination with other
substances and an intoxication of minor severity with 2,5-dimethoxy-4-propylphenethylamine (2C-P). The most frequent
symptoms were tachycardia (28 %), anxiety (23 %), nausea or vomiting (18 %), and agitation (17 %). Severe complications
included two fatalities, two acute myocardial infarctions, seizures (13 cases), and psychosis (six cases). Most patients
(76 %) were discharged home, 10 % were admitted to intensive care, and 2 % were referred to psychiatric care.
Conclusion: Most medical problems related to illicit drugs concerned cocaine and cannabis and mainly included
sympathomimetic toxicity and/or psychiatric disorders confirming data from the prior year. Importantly, despite the
dramatic increase in various NPS being detected in the last years, these substances were infrequently associated with ED
presentations compared with classic recreational drugs.
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Background
The recreational use of psychoactive substances is com-
mon. It is estimated that over 80 million adults, or al-
most a quarter of the adult population in the European
Union have tried illicit drugs at some point in their lives.
The most commonly used drugs are cannabis, cocaine,
amphetamines and 3,4-methylenedioxy-methampheta-
mine (MDMA), however, levels of lifetime use differ
considerably between countries [1]. Collection of sub-
stance use-related data is usually based on indicators
such as custom seizures, drug-related deaths, and sur-
veys, but there is limited systematic collection of data on
acute drug toxicity or hospital presentations. Moreover,
novel psychoactive substances (NPS) have emerged in
the last years in response to market trends and legisla-
tive control [2]. These novel substances (also known as
“designer drugs”, “research chemicals”, “bath salts”,
“plant food”, or “legal highs”) are usually analogues or
derivatives of controlled substances, produced in order
to circumvent regulations and imitate the effects of the
controlled drugs. The number of NPS on Europe’s drug
market has rapidly increased over the last decade. In
2014, 101 NPS were detected for the first time, 81 in
2013 [1]. The novel substances are typically not detect-
able with the usual drug of abuse immunoassays. It is
therefore possible that they can contribute to acute tox-
icities and medical complications, or even deaths and
escape detection. Good organized monitoring systems
for drug-related health emergencies can help to expand
the limited data currently available on acute toxicities of
recreational substances in general and on NPS in par-
ticular, and thus contribute to the prevention of medical
emergencies and to the improvement of the manage-
ment of acute drug toxicity [3, 4].
The present study aimed to describe the acute recre-
ational drug toxicity resulting in attendances to a large
urban emergency department (ED) in Switzerland over the
period of 1 year. Data on demographics, clinical findings,
substances used, and short-term outcome of patients were
collected. Additionally, the study specifically screened for
NPS using liquid chromatography–mass spectrometry/
mass spectrometry (LC-MS/MS). The study was per-
formed for a second year in a row, continuing our previous
study [5]. The study centre is part of the European Drug
Emergencies Network (Euro-DEN), a 2-year project which
has set up a network of sentinel centres across Europe to
collect systematic data on presentations to the ED with
acute drug/NPS toxicity [3, 6].
Methods
This study was approved by the local ethics committee
(Ethikkommission Nordwest- und Zentraschweiz (EKNZ),
Basel, Switzerland). We included all patients admitted to
the ED of the University Hospital of Basel with acute
recreational drug-related medical problems between
October 1st, 2014 and September 30th, 2015. The ED is
both a primary care facility (walk-in patients) and a ter-
tiary referral centre for hospitals in the greater Basel area.
Additionally, all patients brought by paramedics are first
admitted to the ED.
Cases were retrieved in monthly intervals from the
electronic patient chart data-base using a comprehensive
full-text search algorithm. In brief, the sensitive auto-
matic search identified all cases with notions of abuse,
intoxication or related terms and a large number of sub-
stance names including abbreviations and misspellings.
The charts of all cases were reviewed, including notes by
paramedics. Only patients with acute toxicity were in-
cluded. A recreational drug was defined as “a psycho-
active compound that was taken for the purpose of
recreational activities rather than for medical or work
purposes or for self-harm”. We identified the recre-
ational drug(s) associated with the presentation based on
one or a combination of the following: the patient’s self-
reported use, information retrieved from witnesses, the
opinion of the physician assessing the patient, and/or
the analytical confirmation. Cases in which no informa-
tion was available by the patient (e.g. because of coma at
presentation, unwillingness to cooperate, language prob-
lems) but the symptoms and – if available- the analytical
test were typical for an acute recreational drug toxicity,
were also included. Cases with positive analytical tests
without clinical signs of acute toxicity were not included.
Data abstracting was performed in a standardized man-
ner [3, 6] by one of the authors for the entire study. Data
were collected within the Euro-DEN project [3]. Exclu-
sion criteria were: Isolated ethanol intoxication (i.e. self-
report of alcohol use only without analytical evidence of
psychoactive substance co-use, where available), drug
withdrawal and secondary complications of chronic drug
use (e.g. infected injection sites).
We recorded the patient demographics (age, sex, hour
and week day of ED admission), the substances used as
reported by the patient or witnesses, the clinical effects,
and clinical outcome. Clinical variables included the
Glasgow Coma Scale (GCS) score, heart rate, blood
pressure, respiratory rate, body temperature, laboratory
tests and electrocardiography (ECG) findings. Hyperther-
mia was defined as a temperature >39 °C, hypertension as
a systolic blood pressure ≥180 mmHg, hypotension as a
systolic blood pressure ≤90 mmHg. Hallucinations were
defined as any false or altered perception (visual, auditory,
tactile, olfactory or gustatory), psychosis as any episode of
delusions accompanied by confusion, hallucinations and
lack of insight. The severity of poisoning was assessed
using the Poison Severity Score for grading acute poison-
ing [7]. Mild toxicity refers to mild, transient and spontan-
eously resolving symptoms, moderate toxicity refers to
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pronounced or prolonged symptoms, and severe toxicity
indicates severe or life-threatening symptoms.
CEDIA immunoassays (Thermo Fisher Scientific, Passau,
Germany) were used to screen for barbiturates, amphet-
amines (including MDMA), benzodiazepines, cocaine,
cannabis, methadone, and heroin. DRI immunoassays
(Thermo Fisher Scientific, Passau, Germany) were used to
screen for tricyclic antidepressants and opiates. Ethanol
blood levels were determined by an enzyme assay. Add-
itionally, LC-MS/MS analysis with a method covering over
770 substances was applied for confirmation and to detect
additional substances in 78 of the cases (37 %) [8]. Levels
of γ-hydroxybutyrate (GHB) were determined by an en-
zymatic assay (Bühlmann, Allschwil, Switzerland).
Results
During the study period there were 50′624 emergency
department attendances of which 210 were directly re-
lated to acute toxicity of drugs of abuse and therefore in-
cluded in the present study. The demographic data are
presented in Table 1. The mean patient age was 33 years
and most of them were male (73 %). Most patients
were admitted to the ED at night and/or on week-
ends, and half of them (52 %) were brought to the
ED by ambulance.
The most commonly self-reported recreational drugs
were cocaine and cannabis (Fig. 1). There were only 2 cases
of relatively novel substances: A severe intoxication (GCS
3 and hypertension) with paramethoxymethamphetamine
(PMMA) in combination with other substances (MDMA,
methadone, benzodiazepines) and an intoxication of minor
severity (GCS 14 and dizziness) with 2,5-dimethoxy-4-pro-
pylphenethylamine (2C-P), both self-reported without ana-
lytical confirmation. Ten patients (5 %) reported that they
have used a substance without knowing what it was. In 10
cases (5 %) there was no information available on the
agents taken and three patients (1 %) denied having used
any drugs. These patients were included because they were
judged by the assessing physician as being acutely intoxi-
cated based on the symptoms and/or analytical confirm-
ation. Seventy percent of the patients reported use of only
one substance, while use of more than one recreational
drug was reported in 24 % of the cases. Co-use of alcohol
was reported in 48 % of the cases (Table 1).
An analytical drug confirmation was available in 65 %
of the total cases (immunoassay in 136 cases, additional
LC-MS/MS in 78 cases). The most commonly analytic-
ally detected substances were cannabis and cocaine,
followed by opioids (excluding methadone) and benzodi-
azepines (Fig. 2). In 34 % of the cases more than one
substance was analytically confirmed (Table 1).
Table 2 summarizes the medical problems. The most
commonly reported symptoms were tachycardia (28 %),
anxiety (23 %), nausea or vomiting (18 %), and agitation
(17 %). One hundred-two patients (49 %) had an im-
paired consciousness (GCS <15), among them 43 were
unconscious (GCS <8) at presentation or pre-hospital.
Among all 210 cases 46 (22 %) presented with severe in-
toxication and there were two fatalities (one case with
MDMA and one case with heroin) (Table 3). In 28 of
the 46 severe intoxication cases concomitant use of alco-
hol was reported and/or analytically confirmed. Severe
complications further included two acute myocardial in-
farctions (both after use of cocaine, in one case in com-
bination with crystal meth), seizures (13 cases), and
psychosis (six cases) (Table 2). Most patients (76 %) were
medically discharged after spending less than 24 h at the
ED, in 17 cases (8 %) the patients took their own dis-
charge or left the ED before being seen by a doctor.
Twenty patients (10 %) were admitted to the critical care
unit, in nine cases (4 %) the patients were hospital-
ized in wards other than critical care unit, and four
patients (2 %) were admitted to a psychiatric clinic
(Table 3). In 152 cases (72 %) medical treatment in-
cluding oxygen and intravenous fluid administration
Table 1 Patient characteristics
Number of cases,
N = 210 (%)
Male 154 (73)
Female 56 (27)
Age (years)
≤20 36 (17)
21–30 64 (30)
31–40 57 (27)
>40 53 (25)
Time of presentation
Night arrival (20:00 – 8:00 h) 107 (51)
Weekend arrival (Friday 17:00 h – Monday 8:00 h) 109 (52)
Ethanol co-ingested (self-reported)
Yes 101 (48)
No 12 (6)
Not known 97 (46)
Self-reported drug use
1 substance 146 (70)
>1 substances 51 (24)
No drug use 3 (1)
No information available (e.g. coma, incooperative) 10 (5)
Laboratory-confirmed drug use
1 substance 55 (26)
>1 substances 72 (34)
Negative test (absence or insufficient test
sensitivity)
9 (4)
No drug test performed 74 (35)
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was provided. Tracheal intubation was performed in seven
cases (3 %). Sedating drugs (e.g. benzodiazepines, antipsy-
chotics, propofol, ketamine) were administered in 50 cases
(24 %), an antidote (i.e. naloxone, flumazenil, and/or
biperiden) was given in 18 cases (9 %).
Discussion
In this study we described acute medical problems due
to recreational drug use. Cocaine and cannabis were the
substances most commonly self-reported and analytically
detected, while only 2 ED presentations were related to
acute toxicity of NPS including 2C-P and PMMA. The
severity of the intoxication was minor in the majority of
the cases. However, there were two fatalities, one case
with MDMA and one case with heroin. Most medical
problems included sympathomimetic toxicity and/or
psychiatric disorders. Ethanol co-use was reported in al-
most half of the cases and in the majority of the severe
intoxications alcohol co-use was reported and/or analyt-
ically confirmed.
Fig. 1 Self-reported substance use (count of cases)
Fig. 2 Substances analytically confirmed (count of cases)
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In comparison to the data from the same ED from the
prior year (October 1st, 2013 - September 30th, 2014) [5]
there was a similar number of cases (210 in the present
study, 216 in the prior year). The substances most com-
monly associated with presentations to the ED due to
acute drug toxicity were in accordance with the prior
year cocaine and cannabis. There were two presentations
due to NPS acute toxicity in both studies, however,
different NPS were reported each year (delusional para-
sitosis under pentylone and hallucinations under 2,5-
dimethoxy-4-bromophenethylamine (2C-B) in the prior
year). Regarding the chemical structure, all four NPS
seen in both our studies (PMMA, 2C-P, 2C-B, and penty-
lone) were phenethylamines, a large family of monoamine
alkaloids which also includes amphetamine, metham-
phetamine, and MDMA [2, 9]. Phenethylamine is the core
structure of many NPS, but little modification can lead to
significant alterations in pharmacological properties and
clinical actions [2, 9, 10]. PMMA, often sold as MDMA or
in combination with MDMA in ecstasy pills, has been as-
sociated with severe hyperthermia [2, 10, 11]. In the
PMMA case in our study, the 42-year old male patient re-
ported having used “superman-XTC” tablets containing
MDMA and PMMA, in combination with methadone and
diazepam. Symptoms included tachycardia (117 beats per
minute at presentation), hypertension (systolic blood pres-
sure 197 mm Hg at presentation), and a GCS of three pre-
Table 2 Clinical characteristics of acute recreational drug
intoxications
Number of cases,
N = 210 (%)
Cardiovascular
Chest pain 32 (15)
Palpitations 26 (12)
Dyspnea 18 (9)
Hypertension (systolic blood pressure
≥180 mmHg)
5 (2)
Hypotension (systolic blood pressure ≤90 mmHg) 3 (1)
Tachycardia (>100 beats per minute) 58 (28)
Myocardial infarction 2 (1)
Arrhythmias 2 (1)
QTc >450 msec 32 (15)
Psychiatric
Anxiety, nervousness, or fear 49 (23)
Psychosis 6 (3)
Hallucinations 8 (4)
Agitation or aggression 35 (17)
Panic attack 8 (4)
Insomnia 5 (2)
Suicide ideation 1 (<1)
Neurologic
Unconscious (GCS <8) at presentation or
pre-hospital
43 (20)
Impaired consciousness (GCS <15) at
presentation or pre-hospital
102 (49)
Vertigo or dizziness 16 (8)
Headache 6 (3)
Paresthesias 6 (3)
Seizure 13 (6)
Tremor 5 (2)
Amnesia 7 (3)
Cerebellar features (e.g. ataxia) 3 (1)
Miosis 16 (8)
Mydriasis 6 (3)
Respiratory depression 7 (3)
Miscellanous
Hyperventilation 12 (6)
Nausea or vomiting 38 (18)
Diarrhoea 1 (<1)
Sweating 8 (4)
Malaise 6 (3)
Abdominal pain 11 (5)
Hyperthermia >39.0 °C 1 (<1)
Muscle cramps 1 (<1)
Pneumothorax 1 (<1)
Table 2 Clinical characteristics of acute recreational drug
intoxications (Continued)
Injuries (e.g. fracture, wound) 1 (<1)
Epistaxis 2 (1)
Elevated creatine kinase (>250 U/L) 59 (28)
Weakness, walking impairment 2 (1)
Table 3 Severity of poisoning and outcome
Number of cases,
N = 210 (%)
Severity of poisoning
Minor 119 (57)
Moderate 43 (20)
Severe 46 (22)
Fatal 2 (1)
Outcome
Medically discharged home 160 (76)
Self-discharged 17 (8)
Admission to critical care unit 20 (10)
Admission to ward other than critical care unit 9 (4)
Admission to psychiatric clinic 4 (2)
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hospital (14 at presentation), but the body temperature
values were not reported. Because of the multiple sub-
stances used the clinical toxicity may not have been
caused by PMMA alone in this case. 2C-P is a member of
the 2C-series of substituted phenethylamines, a large fam-
ily of hallucinogens characterized by methoxy-groups at
positions 2 and 5 of the benzene ring and different hydro-
phobic substitutions at the 4-position [2, 9, 10]. The case
in our study was a 22-year old male patient who reported
dizziness after consuming alcohol (3 l of beer) together
with a tablet initially thought to contain MDMA but
which later turned out to contain 2C-P. Because of the
co-use of alcohol the reported dizziness and GCS score of
14 cannot be attributed to the 2C-P toxicity alone, if at all.
Similar to the previous year, medical problems mainly
included sympathomimetic toxicity and/or psychiatric
disorders, and most patients could be discharged home.
Severe toxicity was in both studies more frequent in
combination with ethanol use, indicating that factors
which contribute to the characterization of an intoxica-
tion as “severe” (e.g. impaired consciousness) could be in
many cases due to alcohol use and not directly related
to the other recreational substances. Additionally, in 13
cases (46 %) of the severe intoxications with alcohol co-
use (n = 28) other CNS depressants (e.g. benzodiazepines,
opioids, GHB) were self-reported and/or analytically con-
firmed in contrast to only seven cases (25 %) with co-use
of stimulants (e.g. cocaine).
Compared to the prior year there was an increase in
the cases related to heroin (30 vs. 15 self-reported cases),
and a decrease in the cases related to LSD (2 vs. 11 self-
reported cases). However, because of the small sample
size and short period of observation, these trends may
have occurred by chance.
In 16 EDs across Europe the most often reported
drugs used during 1 year (October 1st, 2013 - September
30th, 2014) were heroin, cocaine, and cannabis [6]. Simi-
lar to our findings in Basel, NPS were involved in only
5.6 % (n = 484) of the cases (mainly mephedrone). To-
gether the data indicates that NPS are either consumed
to a lesser extent compared to classical recreational
drugs, and/or show less acute toxicity.
One of the reasons for providing systematic collection
of data on acute psychoactive substance toxicity is to im-
prove recognition and clinical management of drug re-
lated emergencies. Treatment includes in most of the
cases general supportive measures, as for most of the
substances there is no specific antidote available. Specific
therapy is available only for few substances, such as opi-
oids (naloxone) and benzodiazepines (flumazenil). The
opioid antagonist naloxone can reverse the effects of
most opioids within minutes, which may be life-saving
in the case of a massive overdose [12]. In cases of co-use
of opioids with cocaine though, the treatment with
naloxone may lead to life threatening arrhythmias [13].
Although in the present study naloxone was given in six
cases of opioid co-use with cocaine (self-reported and/or
analytically detected), no such complications were re-
ported. In one of the fatality cases in our study, the 19-
year old patient was brought to ED from a night club
with impaired consciousness (GCS 12–13), tachycardia
(180 beats/min), cramps, and foam in his mouth, after
consuming 3 or 4 green pills in diamond shape with a
superman logo (reportedly MDMA and confirmed later
with LC-MS/MS). Shortly after admission, it came to a
rapid deterioration with the GCS dropping to five,
hyperthermia (>42 °C), hypertension, and tachycardia,
initially with a wide complex tachycardia which soon
turned into ventricular fibrillation and finally asystole
and exitus despite reanimation. Intoxication with
MDMA can lead to severe hyperthermia. It is possible
that timely measures to reduce the temperature may
have led to another outcome in this case. Temperature
can be reduced in such cases by removing clothing,
spraying with tepid water, and encouraging evaporative
cooling with fanning. For very high body temperatures
(>40–41 °C), neuromuscular paralysis is used to abolish
muscle activity quickly [12]. Benzodiazepines (e.g. diaze-
pam 0.1–0.3 mg/kg per os, intravenously, or per rectum)
are recommended in the treatment of acute MDMA tox-
icity to suppress CNS sympathetic outflow [14]. In our
case the patient received midazolam before intubation.
Among the substances used for recreational purposes
in our study were also prescription medicines and other
products, not typically associated with recreational use
(Fig. 1). The recreational misuse of prescription drugs in
Europe is an increasing issue of concern. Sedatives and
hypnotics are after opioids the most commonly misused
prescription drugs [15]. Benzodiazepines were the most
common group of recreationally used prescription drugs
in a European study [6]. Reasons for their misuse reported
in surveys included insomnia, stress, and/or to get high
[16]. Pregabalin was also commonly reported across
Europe [6]. Pregabalin may have effects on the dopamin-
ergic system [17] and a potential for misuse [18].
Our study has some limitations. Substances that have
been taken as co-medication (e.g. antidepressants), given
as a treatment by the paramedics (e.g. benzodiazepines),
or can be detected in samples beyond the acute intoxica-
tion (e.g. cannabis) could have been overrepresented in
the analytical results. On the other hand, substances like
GHB, which can be detected only during a very short
time period after use, and synthetic cannabinoids, which
cannot be detected with the LC-MS/MS method used in
the present study, may have gone undetected. Further-
more, there were some missing data in the patient his-
tories, clinical data were not recorded in standardized
manner at presentation, some symptoms described could
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have been the result of withdrawal rather than acute tox-
icity (e.g. seizures associated with alcohol and/or benzo-
diazepine withdrawal), and data from only one ED is not
representative, as it may reflect local trends.
Strengths of our study include the detailed patient and
clinical data documentations used, in contrast to studies
based on coded diagnoses or analyses of poison center
data. Especially, the exposure was confirmed for the ma-
jority of the patients.
Conclusion
In conclusion, most medical problems related to recre-
ational drug toxicity concerned cocaine and cannabis and
mainly included sympathomimetic toxicity and/or psychi-
atric disorders. Similar to the previous year, cases with
acute toxicity linked to NPS appear to be uncommon.
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